Ascendis Pharma AS (FRA:A71) Cyclically Adjusted FCF per Share: €-4.88 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:A71 Ascendis Pharma AS FRA:A71
37 GF Score
Price €206.00
! 5 Warning Signs
View Full Analysis

What is Ascendis Pharma AS Cyclically Adjusted FCF per Share?

Ascendis Pharma AS FRA:A71 +0.98% 37 Cyclically Adjusted FCF per Share is €-4.88 as of Mar. 2026. GuruFocus rates FRA:A71 with a GF Score™ of 37/100. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Ascendis Pharma AS's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.126. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-4.88 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-23), Ascendis Pharma AS's current stock price is €206.00. Ascendis Pharma AS's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-4.88. Ascendis Pharma AS's Cyclically Adjusted Price-to-FCF of today is .


Ascendis Pharma AS  (FRA:A71) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Ascendis Pharma AS Cyclically Adjusted FCF per Share Related Terms


Ascendis Pharma AS Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Ascendis Pharma AS's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS Cyclically Adjusted FCF per Share Chart

Ascendis Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -5.26 -5.96 -4.98

Ascendis Pharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.67 -5.28 -5.25 -4.98 -4.88

FRA:A71 vs JAZZ, BBIO, EXEL: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Ascendis Pharma AS's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma AS Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma AS's Cyclically Adjusted Price-to-FCF falls into.


FRA:A71
37GF Score
Ascendis Pharma AS FRA:A71
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascendis Pharma AS Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ascendis Pharma AS's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.126/121.6800*121.6800
=-0.126

Current CPI (Mar. 2026) = 121.6800.

Ascendis Pharma AS Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.519 100.600 -0.628
201609 -0.635 100.200 -0.771
201612 -0.545 100.300 -0.661
201703 -0.667 101.200 -0.802
201706 -0.742 101.200 -0.892
201709 -0.794 101.800 -0.949
201712 -0.660 101.300 -0.793
201803 -0.952 101.700 -1.139
201806 -0.491 102.300 -0.584
201809 -1.135 102.400 -1.349
201812 -0.871 102.100 -1.038
201903 -1.460 102.900 -1.726
201906 -0.131 102.900 -0.155
201909 -1.286 102.900 -1.521
201912 -1.053 102.900 -1.245
202003 -1.520 103.300 -1.790
202006 -1.276 103.200 -1.504
202009 -1.197 103.500 -1.407
202012 -1.785 103.400 -2.101
202103 -1.603 104.300 -1.870
202106 -2.206 105.000 -2.556
202109 -1.992 105.800 -2.291
202112 -2.254 106.600 -2.573
202203 -2.373 109.900 -2.627
202206 -2.296 113.600 -2.459
202209 -1.827 116.400 -1.910
202212 -2.600 115.900 -2.730
202303 -2.641 117.300 -2.740
202306 -2.732 116.400 -2.856
202309 -2.234 117.400 -2.315
202312 -0.673 116.700 -0.702
202403 -1.789 118.400 -1.839
202406 -1.014 118.500 -1.041
202409 -0.984 118.900 -1.007
202412 -1.464 118.900 -1.498
202503 -0.238 120.200 -0.241
202506 -0.115 120.700 -0.116
202509 0.035 121.600 0.035
202512 1.199 121.200 1.204
202603 -0.126 121.680 -0.126

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-4.88 mean?
Ascendis Pharma AS (FRA:A71) has a Cyclically Adjusted FCF per Share of €-4.88 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Ascendis Pharma AS and its competitors.
Is Ascendis Pharma AS's Cyclically Adjusted FCF per Share too high?
Ascendis Pharma AS's current Cyclically Adjusted FCF per Share is €-4.88. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's Cyclically Adjusted FCF per Share compare to JAZZ and BBIO?
Ascendis Pharma AS's Cyclically Adjusted FCF per Share of €-4.88 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Ascendis Pharma AS and its competitors. Ascendis Pharma AS's current Cyclically Adjusted FCF per Share is €-4.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (FRA:A71) has a current Cyclically Adjusted FCF per Share of €-4.88. The current Cyclically Adjusted FCF per Share is €-4.88. Ascendis Pharma AS's overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Ascendis Pharma AS (FRA:A71), the current Cyclically Adjusted FCF per Share is €-4.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascendis Pharma AS Business Description

Other Exchanges ASND:USA
Address Tuborg Boulevard 12, Hellerup, DNK, 2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score

Get the complete analysis for FRA:A71

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€206.00
Price